What is the Descartes-30 Clinical Trial?

This Phase I/II study is evaluating the safety and feasibility of an investigational cell therapy called Descartes-30 in eligible patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). ARDS typically occurs in people who are already critically ill or who have significant injuries. Patients with ARDS due to COVID-19 who meet eligibility criteria will receive priority enrollment and treatment.

Am I eligible?

A patient is eligible if he/she is 18 years and older and has:

  • a diagnosis of moderate-to-severe ARDS as per Berlin Criteria;
  • been diagnosed with ARDS for less than 96 hours;
  • informed consent from participant or health care proxy

Patients who are currently on ECMO or had recent treatment with Pulmozyme® (dornase alfa) after diagnosis of ARDS will be excluded.

Additional inclusion and exclusion criteria are available on ClinicalTrials.gov.

What To Expect?

Upon intravenous administration, Descartes-30 cells are intended to home to the lungs of patients with ARDS. Once they arrive, the cells secrete a combination of enzymes to eliminate Neutrophil Extracellular Traps (“NETs”), which are inflammatory webs of DNA and toxic proteins that are thought to contribute to ARDS.

How will I receive Descartes-30?

Descartes-30 will be infused into your bloodstream daily for a total of three days. These cells are prepared and shipped to your hospital in advance.


The University of Oklahoma Health Sciences Center
Oklahoma City, OK

Brigham and Women’s Hospital
Boston, MA

Contact us for additional information about the Descartes-30 Clinical Trial

Call Cartesian Clinical Trials at 1-302-648-6497, email us at trials@cartesiantx.com or enter your information below and click the SEND button.


    Your Email *

    Your Phone *

    Your Zip*

    Relationship *